E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to characterise the single dose pharmacokinetic profiles of BeneFIX in male Chinese subjects with Haemophilia B |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety and toleration of single dose BeneFIX in male Chinese subjects with Haemophilia B |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet all of the following criteria;
• Male Chinese subjects 6 years and older (weight ≥20 kg) with moderate to severe hemophilia B (Factor IX activity ≤2%)
• Subjects should not have received infusion of any Factor IX products for at least 4 days before the administration of BeneFIX on Day 1
• Subjects must be in a non-bleeding state before BeneFIX administration on Day 1
• Evidence of personally or legally representative (legal only for pediatric subjects) signed and dated informed consent documentation indicating that the subject has been informed of all pertinent aspects of the study
• Subjects who are willing and able to comply with scheduled visits, treatment plans, laboratory tests and other trial procedures.
|
|
E.4 | Principal exclusion criteria |
Subjects presenting with any of the following will not be included in the study
• Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic (including drug allergies) disease or clinical findings at Screening.
• Diagnosed with any other bleeding disorder in addition to Haemophilia B
• Documented Human Immunodeficiency Virus positive patients
• Current FIX inhibitor or history of FIX inhibitor (defined as ≥Upper Limit of Normal (ULN) of the reporting lab)
• Subjects anticipating elective surgery that may be planned to occur in the 1 month following study entry
• Treated with immunomodulatory therapy within 30 days
• Treated with an investigational drug within 30 days or 5 half-lives preceding the first dose of the study drug
• Subjects with known hypersensitivity to the active substance or to any of the excipients of BeneFIX
• Subjects with known hypersensitivity to Chinese Hamster Ovary cell (CHO cell) proteins
• Subjects with any of hepatic or renal impairment (ALT or AST >3x Upper Limit of Normal (ULN), total bilirubin >2x ULN, serum creatinine >2x ULN), Prothrombin Time >1.5x ULN, Platelet count <80,000 uL
• Unwilling or unable to follow the terms of the protocol
• Any condition which may compromise the subject’s ability to comply with and/or perform study-related activities or that poses a clinical contraindication to study participation, in the opinion of the Investigator or Sponsor
• A positive urine drug screen
• History of regular alcohol consumption exceeding 14 drinks/week for men within 6 months of screening
• Screening supine blood pressure ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) following at least 5 minutes rest
• 12-lead ECG showing QTc >450 msec or QRS >120 msec at screening
• Blood donation of approximately 1 pint within 56 days prior to dosing
• History of sensitivity to heparin or heparin-induced thrombocytopenia
• Unwilling or unable to comply with the Lifestyle Guidelines
• Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase risk associated with study participation.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacokinetic Endpoints:
•Primary study endpoints will be Cmax, AUClast, AUCinf, Tmax, CL, Vss, Kel, t1/2, MRT, incremental recovery of BeneFIX (as measured by FIX activity)
Safety Endpoints:
•Adverse events, laboratory abnormalities, vital signs, inhibitor development, allergic reactions, and thrombogenicity.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 0 |